| Name | Siponimod for Alzheimer's Disease |
| Summary | Siponimod (Mayzent) is an S1P receptor modulator being repositioned from multiple sclerosis to Alzheimer's disease. Phase II trial (NCT06639282) evaluates neuroprotective and anti-inflammatory effects in AD patients. |